AUSTIN, Texas / Jul 31, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30, 2025, after the market closes on August 7, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET).
Earnings Conference Call Information | ||
Event: |
| Natera’s Second Quarter 2025 Financial Results |
Date: |
| August 7, 2025 |
Time: |
| 1:30 p.m. PT (4:30 p.m. ET) |
Live Dial-In: |
| 1-888-770-7321 (Domestic) |
Conference ID: |
| 7684785 |
Webcast: |
| |
A webcast replay will be available at investor.natera.com.
About Natera
Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.
| Last Trade: | US$238.51 |
| Daily Change: | 7.88 3.42 |
| Daily Volume: | 1,281,764 |
| Market Cap: | US$32.920B |
November 12, 2025 November 06, 2025 October 28, 2025 October 20, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
